TW200944233A - Methods for treating or preventing colorectal cancer - Google Patents

Methods for treating or preventing colorectal cancer Download PDF

Info

Publication number
TW200944233A
TW200944233A TW098109578A TW98109578A TW200944233A TW 200944233 A TW200944233 A TW 200944233A TW 098109578 A TW098109578 A TW 098109578A TW 98109578 A TW98109578 A TW 98109578A TW 200944233 A TW200944233 A TW 200944233A
Authority
TW
Taiwan
Prior art keywords
ser
antibody
gly
leu
doc
Prior art date
Application number
TW098109578A
Other languages
English (en)
Chinese (zh)
Inventor
Yaolin Wang
Yan Wang
Ming Liu
Walter Robert Bishop
Cynthia Seidel-Dugan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of TW200944233A publication Critical patent/TW200944233A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW098109578A 2008-03-25 2009-03-24 Methods for treating or preventing colorectal cancer TW200944233A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3919708P 2008-03-25 2008-03-25

Publications (1)

Publication Number Publication Date
TW200944233A true TW200944233A (en) 2009-11-01

Family

ID=41340744

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098109578A TW200944233A (en) 2008-03-25 2009-03-24 Methods for treating or preventing colorectal cancer

Country Status (8)

Country Link
US (1) US20110104256A1 (cg-RX-API-DMAC7.html)
EP (1) EP2259797A2 (cg-RX-API-DMAC7.html)
JP (1) JP2011515478A (cg-RX-API-DMAC7.html)
CA (1) CA2718918A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009000721A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010010480A (cg-RX-API-DMAC7.html)
TW (1) TW200944233A (cg-RX-API-DMAC7.html)
WO (1) WO2009142810A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999734A (zh) * 2014-09-29 2017-08-01 得克萨斯大学体系董事会 针对parp抑制剂的应答的预测和靶向c‑met和parp1的组合疗法
CN113164480A (zh) * 2018-11-14 2021-07-23 学校法人金泽医科大学 用于治疗弥漫性胃癌的药物组合物

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
WO2010056754A2 (en) 2008-11-11 2010-05-20 The Board Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
TWI460178B (zh) 2009-02-12 2014-11-11 Arqule Inc 組合性組成物及治療癌症之方法
LT3000467T (lt) 2009-04-06 2023-04-11 Wyeth Llc Krūties vėžio gydymo schema naudojant neratinibą
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US8580764B2 (en) * 2010-07-01 2013-11-12 Arqule, Inc. Combinational compositions and methods for treatment of cancer
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
WO2012030896A2 (en) 2010-09-01 2012-03-08 Arqule, Inc. Methods for treatment of non-small cell lung cancer
US20150141273A1 (en) * 2012-04-26 2015-05-21 Stichting Vu-Vumc Biomarkers
NL2010276C2 (en) * 2013-02-08 2014-08-11 Stichting Vu Vumc Biomarkers.
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
JP6210640B2 (ja) * 2014-06-19 2017-10-11 大原薬品工業株式会社 ホリナートカルシウム含有錠
EP3281016A1 (en) 2015-04-10 2018-02-14 Applied Proteomics Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
AU2016309002B2 (en) 2015-08-20 2021-07-29 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment
HK1257220A1 (zh) 2015-08-21 2019-10-18 益普生生物制药有限公司 使用包含脂质体伊立替康和奥沙利铂的组合疗法治疗转移性胰腺癌的方法
WO2017136671A1 (en) * 2016-02-04 2017-08-10 Chattterjee Bandana Combination therapy for castration-resistant prostate cancer
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
JP2017210493A (ja) * 2017-09-08 2017-11-30 大原薬品工業株式会社 ホリナートカルシウム含有錠
JP2021036003A (ja) * 2020-12-05 2021-03-04 大原薬品工業株式会社 ホリナートカルシウム含有錠
CN117677398A (zh) * 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084484B (en) * 2001-01-05 2008-09-25 Pfizer Antibodies to insulin-like growth factor i receptor
MXPA04011624A (es) * 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
EP2135879A3 (en) * 2002-06-28 2010-06-23 Domantis Limited Ligand
CN1835975B (zh) * 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
AU2005286190A1 (en) * 2004-09-22 2006-03-30 Cancer Research Technology Ltd. Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
MX2007012896A (es) * 2005-04-15 2007-12-10 Schering Corp Metodos y composiciones para tratamiento o prevencion de cancer.
BRPI0611800A2 (pt) * 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
JP2009520028A (ja) * 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Igfr抑制剤および抗癌剤の併用
EP2007423A2 (en) * 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
EP2405270B1 (en) * 2006-06-30 2013-07-17 Merck Sharp & Dohme Corp. IGFBP2-Biomarker
US20100143340A1 (en) * 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
MX2010012064A (es) * 2008-05-05 2010-12-06 Schering Corp Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106999734A (zh) * 2014-09-29 2017-08-01 得克萨斯大学体系董事会 针对parp抑制剂的应答的预测和靶向c‑met和parp1的组合疗法
CN106999734B (zh) * 2014-09-29 2020-06-16 得克萨斯大学体系董事会 针对parp抑制剂的应答的预测和靶向c-met和parp1的组合疗法
CN113164480A (zh) * 2018-11-14 2021-07-23 学校法人金泽医科大学 用于治疗弥漫性胃癌的药物组合物
CN113164480B (zh) * 2018-11-14 2023-11-28 学校法人金泽医科大学 用于治疗弥漫性胃癌的药物组合物

Also Published As

Publication number Publication date
MX2010010480A (es) 2010-10-15
US20110104256A1 (en) 2011-05-05
CL2009000721A1 (es) 2010-05-14
WO2009142810A3 (en) 2010-07-15
WO2009142810A2 (en) 2009-11-26
JP2011515478A (ja) 2011-05-19
EP2259797A2 (en) 2010-12-15
CA2718918A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
TW200944233A (en) Methods for treating or preventing colorectal cancer
US20110129456A1 (en) Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
CN105102480B (zh) 催乳素受体结合蛋白及其用途
US8216571B2 (en) Fully human anti-VEGF antibodies and methods of using
CN102123712B (zh) 使用igf1r抑制剂治疗癌症的方法
CN101014365B (zh) 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
US20110014117A1 (en) Anti-igf1r
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
NZ564098A (en) Anti-IGF1R antibody formulations
TW201902514A (zh) Pd-1抗體與vegf配體或vegf受體抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2011140518A (ja) 癌を処置または予防するための方法および組成物
WO2008076257A2 (en) Treating cancer with anti-igflr antibody 19d12 = sch 717454
EP4130006A1 (en) Anti-psma antibody-exatecan analogue conjugate and medical use thereof
WO2011057064A1 (en) Igf1r inhibitor based treatment of prostate cancer
BRPI0720924A2 (pt) Métodos de tratamento